Effect of vancomycin therapy for osteomyelitis on colonization by methicillin-resistant Staphylococcus aureus: Lack of emergence of glycopeptide resistance

Infection Control and Hospital Epidemiology

Volumn 24, Issue 9, 2003, Pages 650-654

  Bernard, Louis ^a   Vaudaux, Pierre ^a,b   Vuagnat, Albert ^b   Stern, Richard ^a   Rohner, Peter ^a   Pittet, Didier ^a   Schrenzel, Jacques ^a   Hoffmeyer, Pierre ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

^b St Michel Hospital   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHLORHEXIDINE GLUCONATE; CIPROFLOXACIN; GLYCOPEPTIDE; PSEUDOMONIC ACID; RIFAMPICIN; VANCOMYCIN;

ADULT; AGED; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIAL COLONIZATION; BACTERIUM CULTURE; CLINICAL ARTICLE; CONTROLLED STUDY; DOSE RESPONSE; DRUG DOSE REGIMEN; ERADICATION THERAPY; FEMALE; FOLLOW UP; HUMAN; INGUINAL REGION; LONG TERM CARE; MALE; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; NOSE; OSTEOMYELITIS; PROSPECTIVE STUDY; STAPHYLOCOCCUS AUREUS; TREATMENT OUTCOME; VANCOMYCIN INTERMEDIATE RESISTANT STAPHYLOCOCCUS AUREUS; WOUND;

ADULT; AGED; ANTI-BACTERIAL AGENTS; CARRIER STATE; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; METHICILLIN RESISTANCE; MIDDLE AGED; OSTEOMYELITIS; POPULATION SURVEILLANCE; PROSPECTIVE STUDIES; STAPHYLOCOCCAL INFECTIONS; STAPHYLOCOCCUS AUREUS; VANCOMYCIN;

EID: 0141596117     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/502268     Document Type: Article

References (41)

1. Hiramatsu K, Hanaki H, Ino T, Yabuta K, Oguri T, Tenover FC. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother 1997;40:135-136.
2. Hiramatsu K, Aritaka N, Hanaki H, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet 1997;350:1670-1673.
3. Tenover FC, Lancaster MV, Hill BC, et al. Characterization of staphylococci with reduced susceptibilities to vancomycin and other glycopeptides. J Clin Microbiol 1998;36:1020-1027.
4. Sieradzki K, Roberts RB, Haber SW, Tomasz A. The development of vancomycin resistance in a patient with methicillin-resistant Staphylococcus aureus infection. N Engl J Med 1999;340:517-523.
5. Tabaqchali S. Vancomycin-resistant Staphylococcus aureus: apocalypse now? Lancet 1997;350:1644-1645.
6. Hubert SK, Mohammed JM, Fridkin SK, et al. Glycopeptide-intermediate Staphylococcus aureus: evaluation of a novel screening method and results of a survey of selected U.S. hospitals. J Clin Microbiol 1999;37:3590-3593.
7. Pujol M, Peña C, Pallares R, et al. Nosocomial Staphylococcus aureus bacteremia among nasal carriers of methicillin-resistant and methicillin-susceptible strains. Am J Med 1996;100:509-516.
8. Gentry LO. Antibiotic therapy for osteomyelitis. Infect Dis Clin North Am 1990;4:485-499.
9. Lew DP, Waldvogel FA. Osteomyelitis. N Engl J Med 1997;336:999-1007.
10. Bernard L, El-Hajj, Pron B, et al. Outpatient parenteral antimicrobial therapy (OPAT) for the treatment of osteomyelitis: evaluation of efficacy, tolerance and cost. J Clin Pharm Ther 2001;26:445-451.
11. Gernaat-van der Sluis AJ, Hoogenboom-Verdegaal AM, Edixhoven PJ, et al. Prophylactic mupirocin could reduce orthopedic wound infections: 1,044 patients treated with mupirocin compared with 1,260 historical controls. Acta Orthop Scand 1998;69:412-414.
12. Harbarth S, Martin Y, Rohner P, Henry N, Auckenthaler R, Pittet D. Effect of delayed infection control measures on a hospital outbreak of methicillin-resistant Staphylococcus aureus. J Hosp Infect 2000;46:43-49.
13. National Committee for Clinical Laboratory Standards. Performance Standards for Antimicrobial Disk Susceptibility Tests, 4th ed. Wayne, PA: National Committee for Clinical Laboratory Standards; 1990. Approved standard M2-A4.
14. Walsh TR, Bolmström A, Qwärnström A, et al. Evaluation of current methods for detection of staphylococci with reduced susceptibility to glycopeptides. J Clin Microbiol 2001;39:2439-2444.
15. Tenover FC. Implications of vancomycin-resistant Staphylococcus aureus. J Hosp Infect 1999;43(suppl):S3-S7.
16. Wei MQ, Wang FU, Grubb WB. Use of contour-clamped homogeneous electric field (CHEF) electrophoresis to type methicillin-resistant Staphylococcus aureus. J Med Microbiol 1992;36:172-176.
17. Tenover FC, Arbeit RD, Goering RV, et al. Interpreting chromosomal DNA restriction patterns produced by pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 1995;33:2233-2239.
18. Boyce JM. MRSA patients: proven methods to treat colonization and infection. J Hosp Infect 2001;48(suppl A):S9-S14.
19. Singh N, Paterson DL, Chang FY, et al. Methicillin-resistant Staphylococcus aureus: the other emerging resistant gram-positive coccus among liver transplant recipients. Clin Infect Dis 2000;30:322-327.
20. Martin JN, Perdreau-Remington F, Kartalija M, et al. A randomized clinical trial of mupirocin in the eradication of Staphylococcus aureus nasal carriage in human immunodeficiency virus disease. J Infect Dis 1999;180:896-899.
21. Kluytmans JA, Manders MJ, van Bommel E, Verbrugh H. Elimination of nasal carriage of Staphylococcus aureus in hemodialysis patients. Infect Control Hosp Epidemiol 1996;17:793-797.
22. VandenBergh MF, Kluytmans JA, van Hout BA, et al. Cost-effectiveness of perioperative mupirocin nasal ointment in cardiothoracic surgery. Infect Control Hosp Epidemiol 1996;17:786-792.
23. Cimochowski GE, Harostock MD, Brown R, et al. Intranasal mupirocin reduces sternal wound infection after open heart surgery in diabetics and nondiabetics. Ann Thorac Surg 2001;71:1572-1578.
24. Muder RR, Boldin M, Brennen C, et al. A controlled trial of rifampicin, minocycline, and rifampicin plus minocycline for eradication of methicillin-resistant Staphylococcus aureus in long-term care patients. J Antimicrob Chemother 1994;34:189-190.
25. Asensio A, Guerrero A, Quereda C, et al. Colonization and infection with methicillin-resistant Staphylococcus aureus: associated factors and eradication. Infect Control Hosp Epidemiol 1996;17:20-28.
26. Darouiche R, Wright C, Hamill R, et al. Eradication of colonization by methicillin-resistant Staphylococcus aureus by using oral minocycline-rifampin and topical mupirocin. Antimicrob Agents Chemother 1991;35:1612-1615.
27. Smith SM, Eng RH, Tecson-Tumang F. Ciprofloxacin therapy for methicillin-resistant Staphylococcus aureus infections or colonizations. Antimicrob Agents Chemother 1989;33:181-184.
28. Parras F, Guerrero MC, Bouza E, et al. Comparative study of mupirocin and oral co-trimoxazole plus topical fusidic acid in eradication of nasal carriage of methicillin-resistant Staphylococcus aureus. Antimicrob Agents Chemother 1995;39:175-179.
29. Ellison RT, Judson FN, Peterson LC, et al. Oral rifampin and trimethoprim/sulfamethoxazole therapy in asymptomatic carriers of methicillin-resistant Staphylococcus aureus infections. West J Med 1984;140:735-740.
30. Roccaforte JS, Bittner MJ, Stumpf CA, Preheim LC. Attempts to eradicate methicillin-resistant Staphylococcus aureus colonization with the use of trimethoprim-sulfamethoxazole, rifampin, and bacitracin. Am J Infect Control 1988;16:141-146.
31. Peterson LR, Quick JN, Jensen B, et al. Emergence of ciprofloxacin resistance in nosocomial methicillin-resistant Staphylococcus aureus isolates: resistance during ciprofloxacin plus rifampin therapy for methicillin-resistant S. aureus colonization. Arch Intern Med 1990;150:2151-2155.
32. Chang SC, Hsieh SM, Chen ML, et al. Oral fusidic acid fails to eradicate methicillin-resistant Staphylococcus aureus colonization and results in emergence of fusidic acid-resistant strains. Diagn Microbiol Infect Dis 2000;36:131-136.
33. Mulligan ME, Ruane PJ, Johnston L, et al. Ciprofloxacin for eradication of methicillin-resistant Staphylococcus aureus colonization. Am J Med 1987;82:215-219.
34. Canawati HN, Tuddenham WJ, Sapico FL, et al. Failure of rifampin to eradicate methicillin-resistant Staphylococcus aureus colonization. Clin Ther 1982;4:526-531.
35. Massias L, Dubois C, de Lentdecker P, Brodaty O, Fischler M, Farinotti R. Penetration of vancomycin in uninfected sternal bone. Antimicrob Agents Chemother 1992;36:2539-2541.
36. Kitzes-Cohen R, Farin D, Piva G, et al. Pharmacokinetics of vancomycin administered as prophylaxis before cardiac surgery. Ther Drug Monit 2000;22:661-667.
37. Linares J. The VISA/GISA problem: therapeutic implications. Clin Microbiol Infect 2001;7(suppl 4):8-15.
38. Geisel R, Schmitz FJ, Fluit AC, et al. Emergence, mechanism, and clinical implications of reduced glycopeptide susceptibility in Staphylococcus aureus. Eur J Clin Microbiol Infect Dis 2001;20:685-697.
39. Burnie J, Matthews R, Jiman-Fatami A, Gottardello P, Hodgetts S, D'arcy S. Analysis of 42 cases of septicemia caused by an epidemic strain of methicillin-resistant Staphylococcus aureus: evidence of resistance to vancomycin. Clin Infect Dis 2000;31:684-689.
40. Pina P, Marliere C, Vandenesch F, et al. An outbreak of Staphylococcus aureus strains with reduced susceptibility to glycopeptides in a French general hospital. Clin Infect Dis 2000;31:1306-1308.
41. Hiramatsu K. Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance. Lancet Infect Dis 2001;1:147-155.